Results 1 to 10 of about 21,299 (206)

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17 [PDF]

British Journal of Clinical Pharmacology, 2010
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • CYP2C19 polymorphisms may have clinical consequences in relation to drugs extensively metabolized by the enzyme.• Recently a new variant CYP2C19*17 was discovered.• Unlike other commonly studied variant alleles, notably CYP2C19*2 and CYP2C19*3, which are defective, CYP2C19*17 is associated with enhanced ...
Li-Wan-Po, Alain, Girard, Thierry, Farndon, Peter, Cooley, Candy, Lithgow, James   +4 more
exaly   +4 more sources

The non-linear and linear effects of CYP2C19 metaboliser status on DNA methylation: a methylome-wide association study [PDF]

Clinical Epigenetics
Background CYP2C19 metabolises many medications. Its enzymatic activity can be inferred from genetic variants within CYP2C19 that link to the efficacy of drug treatments and their side effects.
Chen Shen, Mark J. Adams, Eleanor Davyson, Matthew H. Iveson, Simon R. Cox, Sarah E. Harris, Andrew M. McIntosh, Xueyi Shen   +7 more
doaj   +2 more sources

The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping [PDF]

Pharmacogenetics and Genomics, 2014
The polymorphic hepatic enzyme CYP2C19 catalyzes the metabolism of clinically important drugs such as clopidogrel, proton-pump inhibitors, and others and clinical pharmacogenetic testing for clopidogrel is increasingly common. The CYP2C19*10 single-nucleotide polymorphism (SNP) is located 1 bp upstream the CYP2C19*2 SNP.
Taimour Y, Langaee, Hao-Jie, Zhu, Xinwen, Wang, Nihal, El Rouby, John S, Markowitz, Joyce A, Goldstein, Julie A, Johnson   +6 more
openaire   +3 more sources

The impact of CYP2C19 genotype on phenoconversion by concomitant medication

Frontiers in Pharmacology, 2023
Introduction: Pharmacogenetics-informed drug prescribing is increasingly applied in clinical practice. Typically, drug metabolizing phenotypes are determined based on genetic test results, whereupon dosage or drugs are adjusted.
Laura M. de Jong, Soukayna Boussallami, Elena Sánchez-López, Martin Giera, Maarten E. Tushuizen, Menno Hoekstra, Lukas J. A. C. Hawinkels, Robert Rissmann, Robert Rissmann, Robert Rissmann, Jesse J. Swen, Martijn L. Manson   +11 more
doaj   +1 more source

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse

Scientific Reports, 2021
CYP2C19*2 and CYP2C19*17 might influence tamoxifen metabolism and clinical outcome. Our aim was to investigate the effect of CYP2C19 genotypes on tamoxifen concentrations and metabolic ratios (MRs) and breast cancer recurrence in a large cohort of ...
A. B. Sanchez-Spitman, J. J. Swen, V. O. Dezentjé, D. J. A. R. Moes, H. Gelderblom, H. J. Guchelaar   +5 more
doaj   +1 more source

PharmVar GeneFocus: CYP2C19 [PDF]

Clinical Pharmacology & Therapeutics, 2020
The Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele nomenclature for the polymorphic human CYP2C19 gene. CYP2C19 genetic variation impacts the metabolism of many drugs and has been associated with both efficacy and safety issues for several commonly prescribed medications.
Botton, Mariana R., Whirl-Carrillo, Michelle, Del Tredici, Andria L., Sangkuhl, Katrin, Cavallari, Larisa H., Agúndez, José A., Duconge, Jorge, Lee, Ming Ta Michael, Woodahl, Erica L., Claudio-Campos, Karla, Daly, Ann K., Klein, Teri E., Pratt, Victoria M., Scott, Stuart A., Gaedigk, Andrea   +14 more
openaire   +2 more sources

Distribution of a novel CYP2C haplotype in Native American populations

Frontiers in Genetics, 2023
The CYP2C19 gene, located in the CYP2C cluster, encodes the major drug metabolism enzyme CYP2C19. This gene is highly polymorphic and no-function (CYP2C19*2 and CYP2C19*3), reduced function (CYP2C19*9) and increased function (CYP2C19*17) star alleles ...
Vanessa Câmara Fernandes, Marco Antônio M. Pretti, Luiza Tamie Tsuneto, Maria Luiza Petzl-Erler, Guilherme Suarez-Kurtz   +4 more
doaj   +1 more source

Evaluation of changes in cytochrome P450 2C19 activity in type 2 diabetic rats before and after treatment, by using isolated perfused liver model [PDF]

Iranian Journal of Basic Medical Sciences, 2020
Objective(s): Alteration in drug metabolism is very likely in diabetes mellitus. This study assessed changes in CYP2C19 enzymatic activity in the liver using omeprazole as a probe in the animal model of type II diabetes (T2DM) before and after treatment ...
Navid Neyshaburinezhad, Mohammad Reza Rouini, Hanieh Entezari, Hoda Lavasani, Yalda Hosseinzadeh Ardakani   +4 more
doaj   +1 more source

CYP2C19 Genetic Polymorphism in the East of Iran: Its Association with the Severity and Pattern of Coronary Artery Disease [PDF]

Journal of Cardio-Thoracic Medicine, 2019
Introduction: Since there has been a dearth of research on the assessment of CYP2C19 polymorphism in the east of Iran (Khorasan provinces), this study aimed to detect, CYP2C19*2 and CYP2C19*3 allele frequencies among patients with coronary artery disease.
Mahdi Zahedi, Mahmoud Shabestari, Hossein Ayatollahi, Arash Gholoobi   +3 more
doaj   +1 more source

Association of polymorphic variants of CYP2C19, P2RY12, ITGB3, ITGA2 and eNOS3 genes with high residual platelet reactivity while taking clopidogrel and acetylsalicylic acid at different terms of myocardial infarction

Рациональная фармакотерапия в кардиологии, 2023
Aim. Study of the association of polymorphic variants of CYP2C19 (G681A), P2RY12 (H1/H2), ITGB3 (T1565C), ITGA2 (C807T), eNOS3 (T786C) genes with high residual platelet reactivity (HRPR) to clopidogrel and acetylsalicylic acid (ASA) at different terms of
T. P. Pronko, V. A. Snezhitskiy, T. L. Stepuro, A. V. Kapytski   +3 more
doaj   +1 more source